A citation-based method for searching scientific literature

Lee Bowman, Ramon Tiu, Emily Nash Smyth, Melinda Dale Willard, Li Li, Julie Beyrer, Yimei Han, Ambrish Singh. Clin Lung Cancer 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.
Chenyue Zhang, Chenxing Zhang, Jia Li, Haiyong Wang. J Thorac Oncol 2020
7
50

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Amanda J Redig, Marzia Capelletti, Suzanne E Dahlberg, Lynette M Sholl, Stacy Mach, Caitlin Fontes, Yunling Shi, Poornima Chalasani, Pasi A Jänne. Clin Cancer Res 2016
43
50

MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.
Xuanzong Li, Ruozheng Wang, Linlin Wang. Lung Cancer 2020
3
50

Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Julia K Rotow, Philippe Gui, Wei Wu, Victoria M Raymond, Richard B Lanman, Frederic J Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B Corcoran,[...]. Clin Cancer Res 2020
29
50

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
50

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.
Hiroki Sato, Adam J Schoenfeld, Evan Siau, Yue Christine Lu, Huichun Tai, Ken Suzawa, Daisuke Kubota, Allan J W Lui, Besnik Qeriqi, Marissa Mattar,[...]. Clin Cancer Res 2020
10
50

Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.
Yunjian Pan, Chongze Yuan, Chao Cheng, Yiliang Zhang, Yuan Ma, Difan Zheng, Shanbo Zheng, Yuan Li, Yan Jin, Yihua Sun,[...]. Int J Cancer 2019
9
50

ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
Xuanzong Li, Linlin Wang, Jinming Yu. Lung Cancer 2020
1
100


Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
50


Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
Xinqing Lin, Liqiang Wang, Xiaohong Xie, Yinyin Qin, Zhanhong Xie, Ming Ouyang, Chengzhi Zhou. Front Mol Biosci 2020
3
50

Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
Natsumi Matsuoka, Kenji Tsuji, Eiki Ichihara, Takayuki Hara, Kazuhiko Fukushima, Kishio Toma, Shinji Kitamura, Kenichi Inagaki, Hitoshi Sugiyama, Jun Wada. BMC Nephrol 2020
2
50

Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans.
Sunny Wang, Melisa L Wong, Nathan Hamilton, J Ben Davoren, Thierry M Jahan, Louise C Walter. J Clin Oncol 2012
106
50

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Paal F Brunsvig, Tormod Kyrre Guren, Marta Nyakas, Claudius H Steinfeldt-Reisse, Wenche Rasch, Jon Amund Kyte, Hedvig Vidarsdotter Juul, Steinar Aamdal, Gustav Gaudernack, Else Marit Inderberg. Front Immunol 2020
5
50

The epidemiology of lung cancer.
Patricia M de Groot, Carol C Wu, Brett W Carter, Reginald F Munden. Transl Lung Cancer Res 2018
217
50

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
Misako Nagasaka, Yiwei Li, Ammar Sukari, Sai-Hong Ignatius Ou, Mohammed Najeeb Al-Hallak, Asfar S Azmi. Cancer Treat Rev 2020
71
50


Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression.
Kai-hua Lu, Wei Li, Xiang-hua Liu, Ming Sun, Mei-ling Zhang, Wei-qin Wu, Wei-ping Xie, Ya-yi Hou. BMC Cancer 2013
309
50

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.
Shaodong Hong, Nan Chen, Wenfeng Fang, Jianhua Zhan, Qing Liu, Shiyang Kang, Xiaobo He, Lin Liu, Ting Zhou, Jiaxing Huang,[...]. Oncoimmunology 2015
84
50

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Scott Antonia, Sarah B Goldberg, Ani Balmanoukian, Jamie E Chaft, Rachel E Sanborn, Ashok Gupta, Rajesh Narwal, Keith Steele, Yu Gu, Joyson J Karakunnel,[...]. Lancet Oncol 2016
399
50

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.
Jing Liu, Stephen J Blake, Michelle C R Yong, Heidi Harjunpää, Shin Foong Ngiow, Kazuyoshi Takeda, Arabella Young, Jake S O'Donnell, Stacey Allen, Mark J Smyth,[...]. Cancer Discov 2016
308
50

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors.
Hui Yang, Kai Shen, Chenjing Zhu, Qingfang Li, Yunuo Zhao, Xuelei Ma. Drug Des Devel Ther 2018
19
50

Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
Hong Zheng, Xin Liu, Jianhong Zhang, Shawn J Rice, Matthias Wagman, Yaxian Kong, Liuluan Zhu, Junjia Zhu, Monika Joshi, Chandra P Belani. Oncotarget 2016
39
50

Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer.
Sanjana Monirul, Marthe Rigal, Kader Chouahnia, Mélisande Le Jouan, Maxime Apparuit, Adrien Paix, Anne Jacolot, Laurent Zelek, Boris Duchemann. Vaccines (Basel) 2020
3
50

The Terrible Triad of Checkpoint Inhibition: A Case Report of Myasthenia Gravis, Myocarditis, and Myositis Induced by Cemiplimab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma.
Nikeshan Jeyakumar, Mikel Etchegaray, Jason Henry, Laura Lelenwa, Bihong Zhao, Ana Segura, L Maximilian Buja. Case Reports Immunol 2020
14
50

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Mariano Provencio, Ernest Nadal, Amelia Insa, María Rosario García-Campelo, Joaquín Casal-Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez-Abreu, Alex Martínez-Martí, Javier De Castro Carpeño,[...]. Lancet Oncol 2020
91
50

Immune surveillance of tumors.
Jeremy B Swann, Mark J Smyth. J Clin Invest 2007
824
50

Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor.
Vinay Mathew Thomas, Poorva Bindal, Swetha Ann Alexander, Kymberly McDonald. J Oncol Pharm Pract 2020
6
50

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Naiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Michel M van den Heuvel, Manuel Cobo, David Vicente, Alexey Smolin,[...]. JAMA Oncol 2020
135
50

Two Cases of Atezolizumab-Induced Hypophysitis.
Keitaro Kanie, Genzo Iguchi, Hironori Bando, Yasunori Fujita, Yukiko Odake, Kenichi Yoshida, Ryusaku Matsumoto, Hidenori Fukuoka, Wataru Ogawa, Yutaka Takahashi. J Endocr Soc 2017
27
50

Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Liang Wen, Xiuwen Zou, Yiwen Chen, Xueli Bai, Tingbo Liang. Front Immunol 2020
7
50

Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells.
Marzia Del Re, Elena Arrigoni, Giuliana Restante, Antonio Passaro, Eleonora Rofi, Stefania Crucitta, Filippo De Marinis, Antonello Di Paolo, Romano Danesi. Stem Cells 2018
18
50

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.
Luis Teixeira, Jacques Medioni, Julie Garibal, Olivier Adotevi, Ludovic Doucet, Marie-Agnès Dragon Durey, Zineb Ghrieb, Jean-Jacques Kiladjian, Mara Brizard, Caroline Laheurte,[...]. Clin Cancer Res 2020
16
50

The entry of nanoparticles into solid tumours.
Shrey Sindhwani, Abdullah Muhammad Syed, Jessica Ngai, Benjamin R Kingston, Laura Maiorino, Jeremy Rothschild, Presley MacMillan, Yuwei Zhang, Netra Unni Rajesh, Tran Hoang,[...]. Nat Mater 2020
349
50


Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019.
Jean-Bernard Auliac, Sophie Bayle, Pascal Do, Gwenaëlle Le Garff, Magali Roa, Lionel Falchero, Eric Huchot, Gilles Quéré, Gaëlle Jeannin, Anne-Cécile Métivier,[...]. Cancers (Basel) 2020
3
50

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
50

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, Gregg D Fine, Omid Hamid, Michael S Gordon, Jeffery A Sosman, David F McDermott, John D Powderly, Scott N Gettinger,[...]. Nature 2014
50



Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
50


Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Benjamin Herzberg, Meghan J Campo, Justin F Gainor. Oncologist 2017
84
50

Durvalumab-associated vasculitis presenting as 'the blue toe syndrome'.
Shivangi Gupta, Dan Xu, Jane Hadfield, David Prentice. BMJ Case Rep 2020
2
50

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
50

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, Timothy J Price, Gerald S Falchook, Jürgen Wolf, Antoine Italiano, Martin Schuler, Hossein Borghaei, Fabrice Barlesi,[...]. N Engl J Med 2021
53
50


Immunotherapy: Cancer vaccines on the move.
Jacques Banchereau, Karolina Palucka. Nat Rev Clin Oncol 2018
68
50

Pembrolizumab-induced pneumonitis.
Vincent Leroy, Carole Templier, Jean-Baptiste Faivre, Arnaud Scherpereel, Clement Fournier, Laurent Mortier, Lidwine Wemeau-Stervinou. ERJ Open Res 2017
22
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.